Does the media prefer LRMR or ANAB?

In the previous week, Larimar Therapeutics had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Larimar Therapeutics and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.45 beat Larimar Therapeutics' score of 0.43 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LRMR or SRPT?

In the previous week, Sarepta Therapeutics had 12 more articles in the media than Larimar Therapeutics. MarketBeat recorded 23 mentions for Sarepta Therapeutics and 11 mentions for Larimar Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat Larimar Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LRMR or SEPN?

In the previous week, Larimar Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 11 mentions for Larimar Therapeutics and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat Larimar Therapeutics' score of 0.43 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LRMR or XNCR?

In the previous week, Xencor had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 17 mentions for Xencor and 11 mentions for Larimar Therapeutics. Xencor's average media sentiment score of 0.52 beat Larimar Therapeutics' score of 0.43 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LRMR or NTLA?

In the previous week, Intellia Therapeutics had 11 more articles in the media than Larimar Therapeutics. MarketBeat recorded 22 mentions for Intellia Therapeutics and 11 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.43 beat Intellia Therapeutics' score of -0.05 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Larimar Therapeutics (LRMR) Competitors

$4.16 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.13 -0.03 (-0.72%)

As of 08:35 AM Eastern

Compare

LRMR vs. ANAB, SRPT, SEPN, XNCR, and NTLA

Should you buy Larimar Therapeutics stock or one of its competitors? MarketBeat compares Larimar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Larimar Therapeutics include AnaptysBio (ANAB), Sarepta Therapeutics (SRPT), Septerna (SEPN), Xencor (XNCR), and Intellia Therapeutics (NTLA). These companies are all part of the "biotechnology" industry.

How does Larimar Therapeutics compare to AnaptysBio?

Larimar Therapeutics (NASDAQ:LRMR) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

In the previous week, Larimar Therapeutics had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Larimar Therapeutics and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.45 beat Larimar Therapeutics' score of 0.43 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Larimar Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Comparatively, 31.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AnaptysBio has higher revenue and earnings than Larimar Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
AnaptysBio	$234.60M	7.15	-$13.23M	-$1.08	N/A

Larimar Therapeutics presently has a consensus price target of $12.57, indicating a potential upside of 202.20%. AnaptysBio has a consensus price target of $82.00, indicating a potential upside of 44.85%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Larimar Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

Larimar Therapeutics and AnaptysBio tied by winning 8 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Sarepta Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Larimar Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Larimar Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Sarepta Therapeutics	$1.97B	0.90	-$713.41M	-$2.90	N/A

In the previous week, Sarepta Therapeutics had 12 more articles in the media than Larimar Therapeutics. MarketBeat recorded 23 mentions for Sarepta Therapeutics and 11 mentions for Larimar Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat Larimar Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics presently has a consensus target price of $12.57, indicating a potential upside of 202.20%. Sarepta Therapeutics has a consensus target price of $25.06, indicating a potential upside of 49.34%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15

Larimar Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Summary

Larimar Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Septerna?

Larimar Therapeutics (NASDAQ:LRMR) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

In the previous week, Larimar Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 11 mentions for Larimar Therapeutics and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat Larimar Therapeutics' score of 0.43 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

Larimar Therapeutics presently has a consensus target price of $12.57, indicating a potential upside of 202.20%. Septerna has a consensus target price of $45.89, indicating a potential upside of 18.18%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Larimar Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Septerna has higher revenue and earnings than Larimar Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Larimar Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Septerna beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Xencor?

Larimar Therapeutics (NASDAQ:LRMR) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Larimar Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Xencor	-155.59%	-28.66%	-20.38%

In the previous week, Xencor had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 17 mentions for Xencor and 11 mentions for Larimar Therapeutics. Xencor's average media sentiment score of 0.52 beat Larimar Therapeutics' score of 0.43 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics currently has a consensus price target of $12.57, suggesting a potential upside of 202.20%. Xencor has a consensus price target of $24.86, suggesting a potential upside of 19.45%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xencor has higher revenue and earnings than Larimar Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Xencor	$125.58M	12.32	-$91.92M	-$2.17	N/A

Larimar Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Summary

Larimar Therapeutics and Xencor tied by winning 8 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Intellia Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Larimar Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Intellia Therapeutics	$67.67M	24.65	-$412.69M	-$3.36	N/A

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Intellia Therapeutics had 11 more articles in the media than Larimar Therapeutics. MarketBeat recorded 22 mentions for Intellia Therapeutics and 11 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.43 beat Intellia Therapeutics' score of -0.05 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Larimar Therapeutics currently has a consensus target price of $12.57, suggesting a potential upside of 202.20%. Intellia Therapeutics has a consensus target price of $20.85, suggesting a potential upside of 74.66%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Larimar Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Summary

Larimar Therapeutics beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$432.14M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.13	9.02	270.57	25.05
Price / Sales	N/A	1,291.29	659.56	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.43	17.52	11.20	6.43
Net Income	-$165.67M	-$13.25M	$3.45B	$348.10M
7 Day Performance	4.52%	5.02%	3.39%	2.66%
1 Month Performance	-2.80%	-2.12%	-0.72%	-0.85%
1 Year Performance	16.20%	61.49%	77.42%	23.96%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	4.326 of 5 stars	$4.16 flat	$12.57 +202.2%	+16.2%	$432.14M	N/A	N/A	30	Earnings Report Upcoming Earnings
ANAB AnaptysBio	3.1416 of 5 stars	$53.66 +0.6%	$82.00 +52.8%	+169.2%	$1.58B	$234.60M	N/A	100	Gap Down
SRPT Sarepta Therapeutics	3.5748 of 5 stars	$15.88 +6.9%	$24.72 +55.7%	-8.0%	$1.57B	$2.18B	N/A	1,372	Analyst Downgrade Options Volume
SEPN Septerna	2.0939 of 5 stars	$34.98 +1.5%	$45.89 +31.2%	+232.2%	$1.55B	$45.95M	N/A	N/A	Gap Up
XNCR Xencor	2.2653 of 5 stars	$19.40 -4.0%	$24.25 +25.0%	+187.8%	$1.50B	$125.58M	N/A	280	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ANAB, SRPT, SEPN, XNCR, and NTLA

How does Larimar Therapeutics compare to AnaptysBio?

Summary

How does Larimar Therapeutics compare to Sarepta Therapeutics?

Summary

How does Larimar Therapeutics compare to Septerna?

Summary

How does Larimar Therapeutics compare to Xencor?

Summary

How does Larimar Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ANAB, SRPT, SEPN, XNCR, and NTLA

How does Larimar Therapeutics compare to AnaptysBio?

Does the media prefer LRMR or ANAB?

Which has more volatility and risk, LRMR or ANAB?

Do institutionals and insiders have more ownership in LRMR or ANAB?

Which has higher earnings and valuation, LRMR or ANAB?

Do analysts recommend LRMR or ANAB?

Is LRMR or ANAB more profitable?

Summary

How does Larimar Therapeutics compare to Sarepta Therapeutics?

Is LRMR or SRPT more profitable?

Do insiders and institutionals have more ownership in LRMR or SRPT?

Which has better valuation and earnings, LRMR or SRPT?

Does the media prefer LRMR or SRPT?

Do analysts rate LRMR or SRPT?

Which has more volatility & risk, LRMR or SRPT?

Summary

How does Larimar Therapeutics compare to Septerna?

Does the media refer more to LRMR or SEPN?

Which has more volatility and risk, LRMR or SEPN?

Do analysts rate LRMR or SEPN?

Which has stronger earnings & valuation, LRMR or SEPN?

Do insiders & institutionals believe in LRMR or SEPN?

Is LRMR or SEPN more profitable?

Summary

How does Larimar Therapeutics compare to Xencor?

Is LRMR or XNCR more profitable?

Does the media prefer LRMR or XNCR?

Do analysts rate LRMR or XNCR?

Do institutionals and insiders hold more shares of LRMR or XNCR?

Which has stronger earnings and valuation, LRMR or XNCR?

Which has more risk & volatility, LRMR or XNCR?

Summary

How does Larimar Therapeutics compare to Intellia Therapeutics?

Which has better earnings and valuation, LRMR or NTLA?

Do institutionals and insiders hold more shares of LRMR or NTLA?

Is LRMR or NTLA more profitable?

Does the media refer more to LRMR or NTLA?

Do analysts prefer LRMR or NTLA?

Which has more volatility & risk, LRMR or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools